-
Something wrong with this record ?
Polysaccharide-based nanocomplexes for co-encapsulation and controlled release of 5-Fluorouracil and Temozolomide
A. Di Martino, A. Pavelkova, S. Maciulyte, S. Budriene, V. Sedlarik,
Language English Country Netherlands
Document type Journal Article
- MeSH
- Alginates chemistry MeSH
- Antineoplastic Agents, Alkylating chemistry MeSH
- Chitosan chemistry MeSH
- Dacarbazine analogs & derivatives chemistry MeSH
- Drug Combinations MeSH
- Fluorouracil chemistry MeSH
- Glucuronic Acid chemistry MeSH
- Hexuronic Acids chemistry MeSH
- Delayed-Action Preparations chemistry MeSH
- Nanoparticles chemistry MeSH
- Drug Carriers chemistry MeSH
- Pectins chemistry MeSH
- Prodrugs chemistry MeSH
- Drug Compounding MeSH
- Antimetabolites, Antineoplastic chemistry MeSH
- Drug Stability MeSH
- Drug Liberation MeSH
- Publication type
- Journal Article MeSH
Polysaccharide-based nanocomplexes, intended for simultaneous encapsulation and controlled release of 5-Fluorouracil (5-FU) and Temozolomide (TMZ) were developed via the complexation method using chitosan, alginic and polygalacturonic acid. Investigation focused on the influence of polysaccharides on the properties of the system and amelioration of the stability of the drugs, in particular TMZ. The dimensions of particles and their ζ-potential were found to range between 100 and 200nm and -25 to +40mV, respectively. Encapsulation efficiency varied from 16% to over 70%, depending on the given system. The influence of pH on the release and co-release of TMZ and 5-FU was evaluated under different pH conditions. The stability of the loaded drug, in particular TMZ, after release was evaluated and confirmed by LC-MS analysis. Results suggested that the amount of loaded drug(s) and the release rate is connected with the weight ratio of polysaccharides and the pH of the media. One-way ANOVA analysis on the obtained data revealed no interference between the drugs during the encapsulation and release process, and in particular no hydrolysis of TMZ occurred suggesting that CS-ALG and CS-PGA would represent interesting carriers for multi-drug controlled release and drugs protection.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17024007
- 003
- CZ-PrNML
- 005
- 20170831110042.0
- 007
- ta
- 008
- 170720s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejps.2016.05.001 $2 doi
- 035 __
- $a (PubMed)27154260
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Di Martino, Antonio $u Centre of Polymer Systems, University Institute, Tomas Bata University in Zlin, tr. T. Bati 5678, 76001 Zlín, Czech Republic.
- 245 10
- $a Polysaccharide-based nanocomplexes for co-encapsulation and controlled release of 5-Fluorouracil and Temozolomide / $c A. Di Martino, A. Pavelkova, S. Maciulyte, S. Budriene, V. Sedlarik,
- 520 9_
- $a Polysaccharide-based nanocomplexes, intended for simultaneous encapsulation and controlled release of 5-Fluorouracil (5-FU) and Temozolomide (TMZ) were developed via the complexation method using chitosan, alginic and polygalacturonic acid. Investigation focused on the influence of polysaccharides on the properties of the system and amelioration of the stability of the drugs, in particular TMZ. The dimensions of particles and their ζ-potential were found to range between 100 and 200nm and -25 to +40mV, respectively. Encapsulation efficiency varied from 16% to over 70%, depending on the given system. The influence of pH on the release and co-release of TMZ and 5-FU was evaluated under different pH conditions. The stability of the loaded drug, in particular TMZ, after release was evaluated and confirmed by LC-MS analysis. Results suggested that the amount of loaded drug(s) and the release rate is connected with the weight ratio of polysaccharides and the pH of the media. One-way ANOVA analysis on the obtained data revealed no interference between the drugs during the encapsulation and release process, and in particular no hydrolysis of TMZ occurred suggesting that CS-ALG and CS-PGA would represent interesting carriers for multi-drug controlled release and drugs protection.
- 650 _2
- $a algináty $x chemie $7 D000464
- 650 _2
- $a protinádorové antimetabolity $x chemie $7 D000964
- 650 _2
- $a alkylační protinádorové látky $x chemie $7 D018906
- 650 _2
- $a chitosan $x chemie $7 D048271
- 650 _2
- $a dakarbazin $x analogy a deriváty $x chemie $7 D003606
- 650 _2
- $a léky s prodlouženým účinkem $x chemie $7 D003692
- 650 _2
- $a nosiče léků $x chemie $7 D004337
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 _2
- $a příprava léků $7 D004339
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a stabilita léku $7 D004355
- 650 _2
- $a fluoruracil $x chemie $7 D005472
- 650 _2
- $a kyselina glukuronová $x chemie $7 D020723
- 650 _2
- $a kyseliny hexuronové $x chemie $7 D006603
- 650 _2
- $a nanočástice $x chemie $7 D053758
- 650 _2
- $a pektiny $x chemie $7 D010368
- 650 _2
- $a prekurzory léčiv $x chemie $7 D011355
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pavelkova, Alena $u Centre of Polymer Systems, University Institute, Tomas Bata University in Zlin, tr. T. Bati 5678, 76001 Zlín, Czech Republic.
- 700 1_
- $a Maciulyte, Sandra $u Faculty of Chemistry, Vilnius University, Naugarduko 24, LT-03225 Vilnius, Lithuania.
- 700 1_
- $a Budriene, Saulute $u Faculty of Chemistry, Vilnius University, Naugarduko 24, LT-03225 Vilnius, Lithuania.
- 700 1_
- $a Sedlarik, Vladimir $u Centre of Polymer Systems, University Institute, Tomas Bata University in Zlin, tr. T. Bati 5678, 76001 Zlín, Czech Republic. Electronic address: sedlarik@ft.utb.cz.
- 773 0_
- $w MED00001639 $t European journal of pharmaceutical sciences official journal of the European Federation for Pharmaceutical Sciences $x 1879-0720 $g Roč. 92, č. - (2016), s. 276-86
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27154260 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170831110632 $b ABA008
- 999 __
- $a ok $b bmc $g 1239688 $s 984920
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 92 $c - $d 276-86 $e 20160503 $i 1879-0720 $m European journal of pharmaceutical sciences $n Eur. j. pharm. sci. (Print) $x MED00001639
- LZP __
- $a Pubmed-20170720